...
首页> 外文期刊>International Scholarly Research Notices >Long-Term Health-Related Quality of Life of Surgically Treated Pituitary Adenoma Patients: A Descriptive Study
【24h】

Long-Term Health-Related Quality of Life of Surgically Treated Pituitary Adenoma Patients: A Descriptive Study

机译:手术治疗的垂体腺瘤患者的长期健康相关生活质量:一项描述性研究

获取原文

摘要

Context. The literature concerning the health-related quality of life (HRQoL) of patients with surgically treated PA is controversial.Objective. To describe the long-term HRQoL of surgically treated patients in all PA classes.Design and subjects. The 15D, a generic HRQoL instrument producing a 15-dimensional profile and a single 15D index score (a difference ≥0.03 on a 0-1 scale is considered clinically important), was used to assess the HRQoL of a 13-year surgical cohort of PA patients in Northern Finland.Results and Conclusion. Nighty-eight eligible consecutive patients with surgically treated PA were studied at an average of 6.3 years after their latest pituitary operation. The average postoperative 15D profiles in patients with non-functioning PA and in acromegalics without GH-suppressive medical treatment were similar to those of the age-standardized general population. However, after this rather long followup, the mean 15D score and the number of statistically significant 15D dimension impairments, compared with those of their reference population, were 0.11 and 9/15, 0.10 and 3/15, and 0.08 and 7/15 for Cushing’s disease, acromegalics needing somatostatin analog, and prolactinoma patients, respectively. Hypopituitarism with replacement medication was not associated with impaired HRQoL. The somatostatin-analog-associated HRQoL finding warrants further clinical research.
机译:上下文。有关通过手术治疗的PA患者的健康相关生活质量(HRQoL)的文献存在争议。描述所有PA类中接受手术治疗的患者的长期HRQoL。设计和主题。 15D是一种通用的HRQoL仪器,可产生15维轮廓和单个15D指数得分(在0-1量表上差异≥0.03被认为具有临床重要性),用于评估13年外科手术队列的HRQoL芬兰北部的PA患者。结果与结论。在最近的垂体手术后平均6.3年研究了48例合格的接受PA手术治疗的连续患者。非功能性PA患者和未接受GH抑制治疗的肢端肥大症患者的平均术后15D轮廓与年龄标准化的普通人群相似。但是,在进行了相当长的随访之后,与参考人群相比,平均15D得分和统计学上显着的15D维度障碍的数量分别为0.11和9 / 15、0.10和3/15,以及0.08和7/15库欣病,需要生长抑素类似物的肢端肥大症和泌乳素瘤患者。补充药物的垂体功能减退与HRQoL受损无关。生长抑素类似物相关的HRQoL发现值得进一步的临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号